Vasküler Kognitif Bozulmadan Demansa: Tanıdan Tedaviye Güncel Yaklaşımlar
Özet
Vasküler kognitif bozukluk (VKB), serebrovasküler hastalıkların yol açtığı bilişsel bozulmaların spektrumunu temsil eder. VKB, genellikle serebrovasküler hastalıklar ve küçük damar patolojileri ile ilişkilidir. Klinik olarak heterojen seyir gösterir ve sıklıkla karma demansın bir parçasıdır. Hastalığa alt vücut parkinsonizmi ve depresyon, apati, psödobulber palsi gibi nöropsikiyatrik bulgular eşlik edebilir. Tanıda öykü, standardize kognitif testler ve manyetik rezonans görüntüleme kritik rol oynar. Ayırıcı tanıda Alzheimer hastalığından farklı olarak yürütücü işlev bozukluğu ve epizodik belleğin görece korunması VKB için ayırt edici özelliklerdir. Tedavide vasküler risk faktörlerinin kontrolü (hipertansiyon, diyabet, hiperlipidemi) en güçlü koruyucu stratejidir. Akut inme tedavileri, antihipertansifler, bazı antidiyabetik ajanlar ve yaşam tarzı müdahaleleri bilişsel bozulmayı azaltmada umut vericidir. Kolinesteraz inhibitörleri ve memantinin etkinliği sınırlı kalırken, DL-3-n-bütilftalid, kök hücre tedavileri ve nöromodülasyon teknikleri gelecekte potansiyel sunmaktadır. Sonuç olarak, VKB yönetiminde en etkili yaklaşım bireyselleştirilmiş, çok boyutlu stratejilerle risk faktörlerinin kontrolü, yeni moleküllerin araştırılması ve kognitif rehabilitasyonun entegrasyonudur. Gelecekteki çalışmalar, patofizyolojik mekanizmaların daha iyi anlaşılmasına ve hastalığı modifiye edebilecek tedavilerin geliştirilmesine odaklanmalıdır.
Referanslar
Morgan AE, Mc Auley MT. Vascular dementia: From pathobiology to emerging perspectives. Ageing Res Rev. 2024;96:102278.
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-204.
Neuropathology Group. Medical Research Council Cognitive F, Aging S. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357(9251):169-75.
Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003;22(5):265-74.
O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698-706.
Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm. 2010;7(4):433-7.
Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45(1):315-53.
Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523-32.
Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol. 1998;147(6):574-80.
Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006-18.
Liu W, Wong A, Au L, Yang J, Wang Z, Leung EY, et al. Influence of Amyloid-beta on Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study. Stroke. 2015;46(11):3074-80.
Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18.
Weaver NA, Kuijf HJ, Aben HP, Abrigo J, Bae HJ, Barbay M, et al. Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts. Lancet Neurol. 2021;20(6):448-59.
White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci. 2002;977:9-23.
Grinberg LT, Heinsen H. Toward a pathological definition of vascular dementia. J Neurol Sci. 2010;299(1-2):136-8.
Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016;36(1):172-86.
Wiesmann M, Kiliaan AJ, Claassen JA. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab. 2013;33(11):1696-706.
Demuth HU, Dijkhuizen RM, Farr TD, Gelderblom M, Horsburgh K, Iadecola C, et al. Recent progress in translational research on neurovascular and neurodegenerative disorders. Restor Neurol Neurosci. 2017;35(1):87-103.
Bakker EN, Bacskai BJ, Arbel-Ornath M, Aldea R, Bedussi B, Morris AW, et al. Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases. Cell Mol Neurobiol. 2016;36(2):181-94.
Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC, Alzheimer's Disease Neuroimaging I. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun. 2016;7:11934.
El Husseini N, Katzan IL, Rost NS, Blake ML, Byun E, Pendlebury ST, et al. Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2023;54(6):e272-e91.
Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke. 2008;39(1):36-41.
Mok VCT, Lam BYK, Wang Z, Liu W, Au L, Leung EYL, et al. Delayed-onset dementia after stroke or transient ischemic attack. Alzheimers Dement. 2016;12(11):1167-76.
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701.
Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28(3):652-9.
Park JH, Lee SB, Lee TJ, Lee DY, Jhoo JH, Youn JC, et al. Depression in vascular dementia is quantitatively and qualitatively different from depression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23(2):67-73.
Moretti R, Torre P, Antonello RM, Cazzato G. Behavioral alterations and vascular dementia. Neurologist. 2006;12(1):43-7.
Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. J Neurol Neurosurg Psychiatry. 2005;76(10):1337-41.
Ballard C, Neill D, O'Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000;59(2):97-106.
Foley K, Konetzka RT, Bunin A, Yonan C. Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents. Int J Geriatr Psychiatry. 2016;31(7):694-701.
Staekenborg SS, van der Flier WM, van Straaten EC, Lane R, Barkhof F, Scheltens P. Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke. 2008;39(2):317-22.
Thanvi B, Lo N, Robinson T. Vascular parkinsonism--an important cause of parkinsonism in older people. Age Ageing. 2005;34(2):114-9.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-713.
Sokolovic L, Hofmann MJ, Mohammad N, Kukolja J. Neuropsychological differential diagnosis of Alzheimer's disease and vascular dementia: a systematic review with meta-regressions. Front Aging Neurosci. 2023;15:1267434.
Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999;53(4):670-8.
Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-53.
Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e44-e71.
Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75(1):61-71.
Hajjar K, Fulton RL, Diener HC, Lees KR, Collaborators V, Alexandrov A, et al. Does the cognitive measure Cog-4 show improvement among patients treated with thrombolysis after acute stroke? Int J Stroke. 2013;8(8):652-6.
Lopez-Cancio E, Jovin TG, Cobo E, Cerda N, Jimenez M, Gomis M, et al. Endovascular treatment improves cognition after stroke: A secondary analysis of REVASCAT trial. Neurology. 2017;88(3):245-51.
Joundi RA, Smith EE, Mandzia J, Ganesh A, Menon BK, Rempel JL, et al. Effect of Endovascular Thrombectomy for Acute Ischemic Stroke on Cognitive Outcomes: A Secondary Analysis of the ESCAPE Trial. Neurology. 2024;102(10):e209270.
Cerasuolo JO, Mandzia J, Cipriano LE, Kapral MK, Fang J, Hachinski V, et al. Intravenous Thrombolysis After First-Ever Ischemic Stroke and Reduced Incident Dementia Rate. Stroke. 2022;53(4):1170-7.
Bala F, Betzner W, Beland B, McDonald JS, Ganesh A. Reperfusion therapies for ischemic stroke in dementia and cognitive impairment: A systematic review and meta-analysis. Int J Stroke. 2024;19(8):867-75.
Seiffge DJ, Anderson CS. Treatment for intracerebral hemorrhage: Dawn of a new era. Int J Stroke. 2024;19(5):482-9.
Peters R, Breitner J, James S, Jicha GA, Meyer PF, Richards M, et al. Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors. Alzheimers Dement (N Y). 2021;7(1):e12202.
Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020;323(19):1934-44.
Peters R, Warwick J, Anstey KJ, Anderson CS. Blood pressure and dementia: What the SPRINT-MIND trial adds and what we still need to know. Neurology. 2019;92(21):1017-8.
Group SMIftSR, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553-61.
Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43(48):4980-90.
Su C, Wu H, Yang X, Zhao B, Zhao R. The relation between antihypertensive treatment and progression of cerebral small vessel disease: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(30):e26749.
Yang W, Luo H, Ma Y, Si S, Zhao H. Effects of Antihypertensive Drugs on Cognitive Function in Elderly Patients with Hypertension: A Review. Aging Dis. 2021;12(3):841-51.
Wang Y, Li S, Pan Y, Wang M, Liao X, Shi J, et al. The effects of blood pressure on post stroke cognitive impairment: BP and PSCI. J Clin Hypertens (Greenwich). 2021;23(12):2100-5.
den Brok M, van Dalen JW, Abdulrahman H, Larson EB, van Middelaar T, van Gool WA, et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. J Am Med Dir Assoc. 2021;22(7):1386-95 e15.
Hajjar I, Okafor M, McDaniel D, Obideen M, Dee E, Shokouhi M, et al. Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(8):e2012252.
Henley B, Okafor M, Kulshreshtha A, Trammell A, Hajjar I. Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials. Int J Stroke. 2023;18(6):736-44.
Kopczak A, Stringer MS, van den Brink H, Kerkhofs D, Blair GW, van Dinther M, et al. Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial. Lancet Neurol. 2023;22(11):991-1004.
Ho JK, Moriarty F, Manly JJ, Larson EB, Evans DA, Rajan KB, et al. Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis. Hypertension. 2021;78(3):629-43.
Lin Y, Gong Z, Ma C, Wang Z, Wang K. Relationship between glycemic control and cognitive impairment: A systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1126183.
Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N, et al. Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS. Am J Alzheimers Dis Other Demen. 2020;35:1533317519899546.
Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2018;65(4):1225-36.
Ha J, Choi DW, Kim KJ, Kim KY, Nam CM, Kim E. Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. Neurology. 2023;100(17):e1799-e811.
Zhou JB, Tang X, Han M, Yang J, Simo R. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. Metabolism. 2020;109:154265.
Adamou A, Barkas F, Milionis H, Ntaios G. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials. Int J Stroke. 2024;19(8):876-87.
Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, et al. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749-57.
Li Z, Chen X, Vong JSL, Zhao L, Huang J, Yan LYC, et al. Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner. Commun Biol. 2021;4(1):656.
Zhao L, Li Z, Vong JSL, Chen X, Lai HM, Yan LYC, et al. Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain. Nat Commun. 2020;11(1):4413.
Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804-14.
Ren QW, Katherine Teng TH, Tse YK, Wei Tsang CT, Yu SY, Wu MZ, et al. Statins and risks of dementia among patients with heart failure: a population-based retrospective cohort study in Hong Kong. Lancet Reg Health West Pac. 2024;44:101006.
Ip BYM, Ko H, Lam BYK, Au LWC, Lau AYL, Huang J, et al. Current and Future Treatments of Vascular Cognitive Impairment. Stroke. 2024;55(4):822-39.
Yang Z, Wang H, Edwards D, Ding C, Yan L, Brayne C, et al. Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis. Ageing Res Rev. 2020;57:100962.
Katsanos AH, Lioutas VA, Charidimou A, Catanese L, Ng KKH, Perera K, et al. Statin treatment and accrual of covert cerebral ischaemia on neuroimaging: a systematic review and meta-analysis of randomized trials. Eur J Neurol. 2020;27(6):1023-7.
Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pena JM, et al. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43(10):e404-e42.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509-18.
Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020;95(3):e320-e31.
Matsumoto C, Ogawa H, Saito Y, Okada S, Soejima H, Sakuma M, et al. Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. Diabetes Care. 2020;43(2):314-20.
Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur Heart J. 2022;43(21):2010-9.
Xie X, Kou L, Chen X, Yuan P, Li J, Li Y. Association of Aspirin with Dementia or Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Randomized Trials. Neuroepidemiology. 2023;57(4):197-205.
Ip BYM, Lam BYK, Hui VMH, Au LWC, Liu MWT, Shi L, et al. Efficacy and safety of cilostazol in decreasing progression of cerebral white matter hyperintensities-A randomized controlled trial. Alzheimers Dement (N Y). 2022;8(1):e12369.
Kim BC, Youn YC, Jeong JH, Han HJ, Kim JH, Lee JH, et al. Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. Stroke. 2022;53(3):698-709.
Wardlaw JM, Woodhouse LJ, Mhlanga, II, Oatey K, Heye AK, Bamford J, et al. Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial. JAMA Neurol. 2023;80(7):682-92.
Investigators SPS, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817-25.
Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238-51.
Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Salahudeen MS, Garrahy E, et al. Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population-Based Cohort Study. J Am Heart Assoc. 2022;11(7):e023098.
Rahman AA, Michaud J, Dell'Aniello S, Moodie EEM, Brophy JM, Durand M, et al. Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Cohort Study. Neurology. 2023;100(12):e1309-e20.
Fong KY, Chan YH, Wang Y, Yeo C, Rosario BH, Lip GYH, et al. Dementia Risk of Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation: Systematic Review and Meta-Analysis. JACC Asia. 2023;3(5):776-86.
Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14(11):653-66.
Wong A, Yiu S, Lam BYK, Leung KT, Shi L, Lo E, et al. Physical activities attenuate the negative cognitive impact from white matter hyperintensities in stroke and TIA patients with low education. Int J Geriatr Psychiatry. 2019;34(12):1792-8.
Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-63.
Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377-89.
Stephen R, Liu Y, Ngandu T, Antikainen R, Hulkkonen J, Koikkalainen J, et al. Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimers Res Ther. 2019;11(1):53.
Sakurai T, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, Hirakawa A, et al. Japan-Multimodal Intervention Trial for the Prevention of Dementia: A randomized controlled trial. Alzheimers Dement. 2024;20(6):3918-30.
Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13 Suppl 3:S115-23.
Bar KJ, Boettger MK, Seidler N, Mentzel HJ, Terborg C, Sauer H. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke. 2007;38(12):3186-92.
Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004(1):CD004395.
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283-90.
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69(5):448-58.
Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev. 2013;2013(5):CD004744.
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008;24(9):2561-74.
Mok V, Wong A, Ho S, Leung T, Lam WW, Wong KS. Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatr Dis Treat. 2007;3(6):943-8.
Narasimhalu K, Effendy S, Sim CH, Lee JM, Chen I, Hia SB, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand. 2010;121(4):217-24.
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323-30.
Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782-92.
Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7(4):310-8.
Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834-9.
Wilcock G, Mobius HJ, Stoffler A, group MMM. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297-305.
Wang A, Jia B, Zhang X, Huo X, Chen J, Gui L, et al. Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2023;80(8):851-9.
Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 2016;12(2):89-99.
Fan X, Shen W, Wang L, Zhang Y. Efficacy and Safety of DL-3-n-Butylphthalide in the Treatment of Poststroke Cognitive Impairment: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:810297.
Dang C, Wang Q, Zhuang Y, Li Q, Feng L, Xiong Y, et al. Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis. Front Pharmacol. 2024;15:1451032.
Liu P, Liu X, Chen J, Zhang Y, Chen J, Yu L, et al. Butylphthalide combined with donepezil for the treatment of vascular dementia: a meta-analysis. J Int Med Res. 2024;52(3):3000605231223081.
Master YL, Wei-Meng Tian B, Xing-Fang Jin M, Zong-Liu Hou P, Jing-Ping-Wang B, Yun-Shan Zhang B, et al. A clinical research of 11cases of human umbilical cord mesenchymal stem cells for curing senile vascular dementia. Transpl Immunol. 2022;74:101669.
Cha B, Kim J, Kim JM, Choi JW, Choi J, Kim K, et al. Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation for Post-stroke Vascular Cognitive Impairment: A Prospective Pilot Study. Front Neurol. 2022;13:813597.
Li KP, Sun J, Wu CQ, An XF, Wu JJ, Zheng MX, et al. Effects of repetitive transcranial magnetic stimulation on post-stroke patients with cognitive impairment: A systematic review and meta-analysis. Behav Brain Res. 2023;439:114229.
Figeys M, Zeeman M, Kim ES. Effects of Transcranial Direct Current Stimulation (tDCS) on Cognitive Performance and Cerebral Oxygen Hemodynamics: A Systematic Review. Front Hum Neurosci. 2021;15:623315.
